Department of Ophthalmology, Medical University of Warsaw, Warsaw, Poland.
Department of Ophthalmology, Medical Centre for Postgraduate Education, Warsaw, Poland.
J Ocul Pharmacol Ther. 2020 Dec;36(10):740-746. doi: 10.1089/jop.2020.0001. Epub 2020 Nov 4.
To evaluate the effect of Mydrane (contains tropicamide, phenylephrine hydrochloride, and lidocaine hydrochloride) on time needed to induce mydriasis and mydriasis stability during cataract surgery. This was an observational, non-interventional, multicenter study of patients undergoing cataract surgery who received Mydrane for mydriasis and intraocular anesthesia. The study was conducted at seven ophthalmology departments at university hospitals in Poland. Patients admitted for cataract surgery within a 2-week period were asked to participate in the study. Patients whose pupils dilated to a diameter ≥6 mm after topical mydriatic administration during preoperative examinations were scheduled to receive Mydrane and included in the registry. No additional inclusion criteria were used. Patients' medical histories, examination results, and operative details were recorded. Pupil diameter was measured during surgery. Surgeons were asked to complete a Likert-based survey in parallel. A total of 307 patients were enrolled. The mean pupil diameter was 7.0 ± 1.0 mm before capsulorhexis and 6.9 ± 1.2 mm before lens implementation. A pupil diameter ≥6 mm was achieved in 91.9% and 87.6% of patients before capsulorhexis and lens implantation, respectively. We asked 58 surgeons whether they agreed with the statement "Mydriasis was obtained in a short time after the administration of Mydrane"; the surgeons agreed with this statement after 92.2% (283/307) of surgeries. In addition, after 88.2% of surgeries, the surgeons agreed with the statement "Mydriasis was stable after the administration of Mydrane." Mydriasis was rapidly and stably obtained after Mydrane injection, as demonstrated by pupil diameter measurements during surgery and surgeons' feedback.
评估 Mydrane(含有托品酰胺、盐酸苯肾上腺素和盐酸利多卡因)在白内障手术中引起散瞳和散瞳稳定性所需的时间的效果。这是一项观察性、非干预性、多中心研究,纳入了接受 Mydrane 散瞳和眼内麻醉的白内障手术患者。该研究在波兰七所大学附属医院的七个眼科部门进行。在两周内接受白内障手术的患者被邀请参与研究。在术前检查中局部使用散瞳剂后瞳孔直径扩大至≥6mm 的患者被安排接受 Mydrane 治疗并纳入登记。未使用其他纳入标准。记录患者的病史、检查结果和手术细节。在手术过程中测量瞳孔直径。同时要求外科医生完成基于李克特量表的调查。共纳入 307 名患者。在撕囊前平均瞳孔直径为 7.0±1.0mm,在植入晶状体前为 6.9±1.2mm。分别有 91.9%和 87.6%的患者在撕囊前和晶状体植入前达到≥6mm 的瞳孔直径。我们询问了 58 名外科医生是否同意“在给予 Mydrane 后短时间内获得散瞳”这一说法;在 307 例手术中的 283 例(92.2%)中,外科医生对此表示同意。此外,在 88.2%的手术中,外科医生同意“在给予 Mydrane 后散瞳稳定”这一说法。Mydrane 注射后迅速且稳定地引起散瞳,这一点通过手术过程中的瞳孔直径测量和外科医生的反馈得到了证实。